Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Current Leases (2019 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Current Leases for 7 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Leases fell 1.8% year-over-year to $1.2 million, compared with a TTM value of $1.2 million through Sep 2025, down 1.8%, and an annual FY2024 reading of $1.3 million, up 13.83% over the prior year.
  • Current Leases was $1.2 million for Q3 2025 at X4 Pharmaceuticals, down from $1.4 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.4 million in Q2 2025 and bottomed at $875000.0 in Q1 2021.
  • Average Current Leases over 5 years is $1.1 million, with a median of $1.1 million recorded in 2023.
  • The sharpest move saw Current Leases soared 37.7% in 2021, then fell 8.26% in 2023.
  • Year by year, Current Leases stood at $1.1 million in 2021, then increased by 11.44% to $1.2 million in 2022, then dropped by 8.26% to $1.1 million in 2023, then rose by 13.83% to $1.3 million in 2024, then dropped by 4.08% to $1.2 million in 2025.
  • Business Quant data shows Current Leases for XFOR at $1.2 million in Q3 2025, $1.4 million in Q2 2025, and $1.3 million in Q1 2025.